Answers are grounded in this paper and cite their sources.
Once-weekly treatment with insulin icodec had glucose-lowering efficacy and a safety profile similar to those of once-daily insulin glargine U100 in patients with type 2 diabetes. (Funded by Novo Nordisk; NN1436-4383 ClinicalTrials.gov number, NCT03751657.).
No takes yet. Share an insight, caveat, or question.
Rosenstock et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: